Skip to main content
. Author manuscript; available in PMC: 2015 May 1.
Published in final edited form as: J Thorac Oncol. 2014 May;9(5):612–621. doi: 10.1097/JTO.0000000000000152

Table 3.

Baseline characteristics, treatment-related variables, and long-term outcomes in patients with clinical stage IIIA NSCLC who received combination therapy with chemotherapy and radiation versus those who received trimodality therapy. This table shows an unmatched comparison. The CR group refers to patients who received chemotherapy and radiation in any sequence. The trimodality group refers to patients who underwent preoperative chemotherapy and radiation therapy.

Chemotherapy and
Radiation (CR) (n=51979)		 Preoperative Chemotherapy
and Radiation (Trimodality)
(n=2293)		 P
value
Age (years) 66.3 ± 10.0 60.8 ± 9.8 <.001
Male Gender 30133 (58.0%) 1166 (50.9%) <.001
Caucasian 44935 (87.1%) 2029 (89.2%) .003
Urban Location 32182 (65.2%) 1506 (70.9%) <.001
Income >$35000/year 30876 (62.4%) 1552 (72.2%) <.001
Charlson/Deyo Score(n=35717 CR, n=2293 Trimodality) 0  23774 (66.6%)
1  8669 (24.3%)
2  3274 (9.2%)		 0  1546 (67.4%)
1  607 (26.5%)
2  140 (6.1%)		 <.001
Distance traveled for treatment (miles) 37.5 ± 387.0 111.8 ± 876.5 <.001
Tumor Size (mm) 48.1 ± 39.5 44.6 ± 30.1 <.001
Facility Reporting Case Community Cancer Program: 9464 (18.2%)
Comprehensive Community Cancer Program: 28183 (54.2%)
Academic/Research Program: 13537 (26.0%)
Other: 795 (1.5%)		 Community Cancer Program: 260 (11.3%)
Comprehensive Community Cancer Program: 1120 (48.8%)
Academic/Research Program: 892 (38.9%)
Other: 21 (0.9%)		 <.001
Chemotherapy Type Single agent: 4193 (9.1%)
Multiagent: 42082 (90.9%)		 Single agent: 83 (4.1%)
Multiagent: 1940 (95.9%)
Chemotherapy-Surgery Sequence (available n=2293) Before surgery: 1912 (83.4%)
Before and After: 381 (16.6%)
Cumulative radiation dose (cGy) 5914.1 ± 3831.8 (26.6% Missing) 5249.1 ± 2339.9 (10.3% Missing) <.001
Cumulative radiation dose (cGy) (n=2059) ≤3500: 37 (1.8%)
3501–4500: 744 (36.1%)
>4500: 1278 (62.1%)
Cumulative radiation dose (cGy) (n=38166) ≤4000: 5678 (14.9%)
4001–5000: 4032 (10.6%)
5001–6000: 7643 (20.0%)
>6000: 20813 (54.5%)
Radiation Surgery Sequence Before surgery: 2220 (96.8%)
Before and after surgery: 73 (3.2%)
Type of operation Lobectomy: 1816 (79.2%)
Pneumonectomy: 342 (14.9%)
Other: 135 (5.9%)
Median Survival (months) 15.7 ± 0.1 36.0 ± 1.5 <.001